CareLit Fachartikel

Efficacy and safety of once weekly dulaglutide and once daily insulin glargine treatment at 52 weeks in patients with type 2 diabetes (T2DM) in the Assessment of Weekly AdministRa…

J Vora, V Pechtner, N Jia, R Shaginian, O Adetunji · Diabetologie und Stoffwechsel · 2015 · Heft 04

Dokument
1175419
CareLit-ID
Jahr
2015
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Diabetologie und Stoffwechsel
Autor:innen
J Vora, V Pechtner, N Jia, R Shaginian, O Adetunji
Ausgabe
Heft 04 / 2015
Seiten
–
Erschienen: 2015-04-29 00:00:00
ISSN
1861-9002
DOI
10.1055/s-0035-1549549

Zusammenfassung

Introduction: We determined the impact of duration of diabetes (DoD) on the efficacy and safety of dulaglutide and insulin glargine treatment in patients with T2DM. Methods: Post hoc subgroup efficacy and safety analyses at 52 weeks were performed by baseline DoD (< 5, ≥5-< 10, ≥10 years) for patients (N = 807; mean [standard deviation] disease duration, 9.1 (6.0) years) receiving dulaglutide 1.5 mg (N = 273), dulaglutide 0.75 mg (N = 272) or insulin glargine (N = 262), all combined with metformin and glimepiride. Results: Baseline patient characteristics were similar between treatment groups according to DoD. F…

Schlagworte

Dulaglutide Years Insulin Glargine Treatment Patients Baseline Hba1C Efficacy Safety Diabetes Duration Diabetologie und Stoffwechsel